The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

X-ELIO, a global leader in renewable energy, has signed a multi-buyer Power Purchase Agreement (PPA) with an Energize program ...

NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...

Barclays analyst Iain Simpson maintained a Buy rating on Haleon PLC (HLN – Research Report) today and set a price target of £4.15. The ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...